156 related articles for article (PubMed ID: 14764580)
1. Mapping the interaction between high molecular mass kininogen and the urokinase plasminogen activator receptor.
Mahdi F; Shariat-Madar Z; Kuo A; Carinato M; Cines DB; Schmaier AH
J Biol Chem; 2004 Apr; 279(16):16621-8. PubMed ID: 14764580
[TBL] [Abstract][Full Text] [Related]
2. Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells.
Mahdi F; Shariat-Madar Z; Todd RF; Figueroa CD; Schmaier AH
Blood; 2001 Apr; 97(8):2342-50. PubMed ID: 11290596
[TBL] [Abstract][Full Text] [Related]
3. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor.
Colman RW; Pixley RA; Najamunnisa S; Yan W; Wang J; Mazar A; McCrae KR
J Clin Invest; 1997 Sep; 100(6):1481-7. PubMed ID: 9294114
[TBL] [Abstract][Full Text] [Related]
4. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.
Chavakis T; Kanse SM; Yutzy B; Lijnen HR; Preissner KT
Blood; 1998 Apr; 91(7):2305-12. PubMed ID: 9516128
[TBL] [Abstract][Full Text] [Related]
5. Interaction of high-molecular-weight kininogen with endothelial cell binding proteins suPAR, gC1qR and cytokeratin 1 determined by surface plasmon resonance (BiaCore).
Pixley RA; Espinola RG; Ghebrehiwet B; Joseph K; Kao A; Bdeir K; Cines DB; Colman RW
Thromb Haemost; 2011 Jun; 105(6):1053-9. PubMed ID: 21544310
[TBL] [Abstract][Full Text] [Related]
6. The carboxyl terminus of bradykinin and amino terminus of the light chain of kininogens comprise an endothelial cell binding domain.
Hasan AA; Cines DB; Zhang J; Schmaier AH
J Biol Chem; 1994 Dec; 269(50):31822-30. PubMed ID: 7989355
[TBL] [Abstract][Full Text] [Related]
7. Mapping binding domains of kininogens on endothelial cell cytokeratin 1.
Shariat-Madar Z; Mahdi F; Schmaier AH
J Biol Chem; 1999 Mar; 274(11):7137-45. PubMed ID: 10066772
[TBL] [Abstract][Full Text] [Related]
8. High molecular weight kininogen and factor XII binding to endothelial cells and astrocytes.
Fernando LP; Natesan S; Joseph K; Kaplan AP
Thromb Haemost; 2003 Nov; 90(5):787-95. PubMed ID: 14597972
[TBL] [Abstract][Full Text] [Related]
9. Factor XI, but not prekallikrein, blocks high molecular weight kininogen binding to human umbilical vein endothelial cells.
Baird TR; Walsh PN
J Biol Chem; 2003 Jun; 278(23):20618-23. PubMed ID: 12663668
[TBL] [Abstract][Full Text] [Related]
10. Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β1-integrin and VEGFR2.
Larusch GA; Merkulova A; Mahdi F; Shariat-Madar Z; Sitrin RG; Cines DB; Schmaier AH
Am J Physiol Heart Circ Physiol; 2013 Aug; 305(3):H305-20. PubMed ID: 23709605
[TBL] [Abstract][Full Text] [Related]
11. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes.
Mahdi F; Madar ZS; Figueroa CD; Schmaier AH
Blood; 2002 May; 99(10):3585-96. PubMed ID: 11986212
[TBL] [Abstract][Full Text] [Related]
12. Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143).
Huang M; Mazar AP; Parry G; Higazi AA; Kuo A; Cines DB
Acta Crystallogr D Biol Crystallogr; 2005 Jun; 61(Pt 6):697-700. PubMed ID: 15930623
[TBL] [Abstract][Full Text] [Related]
13. Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions.
Chavakis T; Kanse SM; Lupu F; Hammes HP; Müller-Esterl W; Pixley RA; Colman RW; Preissner KT
Blood; 2000 Jul; 96(2):514-22. PubMed ID: 10887113
[TBL] [Abstract][Full Text] [Related]
14. Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains.
Behrendt N; Ronne E; Dano K
J Biol Chem; 1996 Sep; 271(37):22885-94. PubMed ID: 8798468
[TBL] [Abstract][Full Text] [Related]
15. Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells.
Joseph K; Ghebrehiwet B; Kaplan AP
Clin Immunol; 1999 Sep; 92(3):246-55. PubMed ID: 10479529
[TBL] [Abstract][Full Text] [Related]
16. Assembly of high molecular weight kininogen and activation of prekallikrein on cell matrix.
Motta G; Shariat-Madar Z; Mahdi F; Sampaio CA; Schmaier AH
Thromb Haemost; 2001 Sep; 86(3):840-7. PubMed ID: 11583317
[TBL] [Abstract][Full Text] [Related]
17. Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins.
Higazi AA; Upson RH; Cohen RL; Manuppello J; Bognacki J; Henkin J; McCrae KR; Kounnas MZ; Strickland DK; Preissner KT; Lawler J; Cines DB
Blood; 1996 Jul; 88(2):542-51. PubMed ID: 8695802
[TBL] [Abstract][Full Text] [Related]
18. High molecular weight kininogen binds phosphatidylserine and opsonizes urokinase plasminogen activator receptor-mediated efferocytosis.
Yang A; Dai J; Xie Z; Colman RW; Wu Q; Birge RB; Wu Y
J Immunol; 2014 May; 192(9):4398-408. PubMed ID: 24688027
[TBL] [Abstract][Full Text] [Related]
19. The kringle stabilizes urokinase binding to the urokinase receptor.
Bdeir K; Kuo A; Sachais BS; Rux AH; Bdeir Y; Mazar A; Higazi AA; Cines DB
Blood; 2003 Nov; 102(10):3600-8. PubMed ID: 12881310
[TBL] [Abstract][Full Text] [Related]
20. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation.
Lin Y; Harris RB; Yan W; McCrae KR; Zhang H; Colman RW
Blood; 1997 Jul; 90(2):690-7. PubMed ID: 9226169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
